Tag: results

Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announces that the listing of its ordinary shares on the regulated market of Euronext Paris will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. CEST.

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Globant S.A. (NYSE: GLOB) between February 15, 2024 and August 14, 2025, inclusive (the “Class Period”), of the important June 23, 2026 lead plaintiff deadline.

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH).

LONDON, June 02, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD), a global HealthTech company advancing wellness through evidence-based, personalized nutrition solutions, is pleased to provide investors with further insight into the progression of its AI-powered agentic infrastructure across both investor and consumer-facing operations following completion of its recently announced Australian wellness platform transaction.

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock on the New York Stock Exchange (“NYSE”) of Stellantis N.V. (NYSE: STLA) between February 26, 2025 and February 5, 2026, inclusive (the “Class Period”), of the important June 8, 2026 lead plaintiff deadline.

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of AeroVironment, Inc. (NASDAQ: AVAV) between June 25, 2025 and March 10, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026.

Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　 announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.